Subcutaneous luteal phase progesterone rescue rectifies ongoing pregnancy rates in hormone replacement therapy vitrified–warmed blastocyst transfer cycles
| Autor: | Gurkan Bozdag, İrem Y Özbek, Mehtap Polat, Hakan Yarali, Murat Erden, Sezcan Mumusoglu, Peter Humaidan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
0301 basic medicine Pregnancy Rate Hormone Replacement Therapy Injections Subcutaneous medicine.medical_treatment Serum progesterone Luteal Phase Luteal phase Andrology Subcutaneous progesterone supplementation 03 medical and health sciences 0302 clinical medicine Pregnancy Ongoing pregnancy medicine Humans In patient Progesterone 030219 obstetrics & reproductive medicine business.industry Blastocyst Transfer Vitrified–warmed embryo transfer Outcome measures Obstetrics and Gynecology Hormone replacement therapy (menopause) Embryo Transfer Embryo transfer 030104 developmental biology Hormone replacement therapy Luteal phase rescue Reproductive Medicine Case-Control Studies Female Progestins business Developmental Biology |
| Zdroj: | Yarali, H, Polat, M, Mumusoglu, S, Ozbek, I Y, Erden, M, Bozdag, G & Humaidan, P 2021, ' Subcutaneous luteal phase progesterone rescue rectifies ongoing pregnancy rates in hormone replacement therapy vitrified–warmed blastocyst transfer cycles ', Reproductive BioMedicine Online, vol. 43, no. 1, pp. 45-51 . https://doi.org/10.1016/j.rbmo.2021.04.011 |
| ISSN: | 1472-6483 |
| DOI: | 10.1016/j.rbmo.2021.04.011 |
| Popis: | Research question: Will luteal phase rescue with additional progesterone increase serum progesterone concentrations and improve reproductive outcomes in patients with low serum progesterone concentrations undergoing hormone replacement therapy (HRT) cycles? Design: Case–control study including 40 consecutive patients with serum progesterone concentrations 8.75 ng/ml on the 5th day of progesterone administration served as controls (n = 120). The main outcome measure was ongoing pregnancy rate (OPR). Results: Baseline demographic features and embryological data of the rescue and control groups were comparable. As expected, the mean serum progesterone concentration was lower in the rescue group on the 5th day of progesterone administration (7.84 ± 0.92 versus 15.32 ± 5.02 ng/ml; P < 0.001). Following rescue, the mean serum progesterone concentration on the day of vitrified–warmed embryo transfer (6th day of progesterone administration) was 33.43 ± 10.83 ng/ml (range 14.61–82.64 ng/ml), and the OPR of the rescue and control groups were comparable. Conclusions: In patients undergoing HRT vitrified–warmed blastocyst transfer with serum progesterone concentrations lower than 8.75 ng/ml 1 day prior to the scheduled embryo transfer (6th day of progesterone administration), additional supplementation with a 25 mg s.c. daily progesterone dose seems to rescue the cycle, resulting in OPR comparable to those of patients with serum progesterone >8.75 ng/ml. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect